Promoter architecture of mouse olfactory receptor genes.

Odorous chemicals are detected by the mouse main olfactory epithelium (MOE) by about 1100 types of olfactory receptors (OR) expressed by olfactory sensory neurons (OSNs). Each mature OSN is thought to express only one allele of a single OR gene. Major impediments to understand the transcriptional control of OR gene expression are the lack of a proper characterization of OR transcription start sites (TSSs) and promoters, and of regulatory transcripts at OR loci. We have applied the nanoCAGE technology to profile the transcriptome and the active promoters in the MOE. nanoCAGE analysis revealed the map and architecture of promoters for 87.5% of the mouse OR genes, as well as the expression of many novel noncoding RNAs including antisense transcripts. We identified candidate transcription factors for OR gene expression and among them confirmed by chromatin immunoprecipitation the binding of TBP, EBF1 (OLF1), and MEF2A to OR promoters. Finally, we showed that a short genomic fragment flanking the major TSS of the OR gene Olfr160 (M72) can drive OSN-specific expression in transgenic mice.

Update of the FANTOM web resource: from mammalian transcriptional landscape to its dynamic regulation.

The international Functional Annotation Of the Mammalian Genomes 4 (FANTOM4) research collaboration set out to better understand the transcriptional network that regulates macrophage differentiation and to uncover novel components of the transcriptome employing a series of high-throughput experiments. The primary and unique technique is cap analysis of gene expression (CAGE), sequencing mRNA 5'-ends with a second-generation sequencer to quantify promoter activities even in the absence of gene annotation. Additional genome-wide experiments complement the setup including short RNA sequencing, microarray gene expression profiling on large-scale perturbation experiments and ChIP-chip for epigenetic marks and transcription factors. All the experiments are performed in a differentiation time course of the THP-1 human leukemic cell line. Furthermore, we performed a large-scale mammalian two-hybrid (M2H) assay between transcription factors and monitored their expression profile across human and mouse tissues with qRT-PCR to address combinatorial effects of regulation by transcription factors. These interdependent data have been analyzed individually and in combination with each other and are published in related but distinct papers. We provide all data together with systematic annotation in an integrated view as resource for the scientific community (http://fantom.gsc.riken.jp/4/). Additionally, we assembled a rich set of derived analysis results including published predicted and validated regulatory interactions. Here we introduce the resource and its update after the initial release.

Indicator displacement assays as molecular timers

Dynamic mixtures of Rh-dye complexes can be used to determine the history of chemical events such as the addition of ATP and ADP by UV-vis spectroscopy.

Mit Klios Augen : das Bild als historische Quelle

Die Trennung zwischen den verschiedenen Fachdisziplinen wurde in den letzten Jahren in verstärktem Maße befragt und hinsichtlich durchlässiger Stellen untersucht, die einen über monodisziplinäre Betrachtungen nicht erreichbaren Erkenntnisgewinn versprechen. Aus diesem Interesse an einer intensivierten interdisziplinären Zusammenarbeit ergeben sich nicht zuletzt auch für Geschichte und Kunstgeschichte neue Möglichkeiten, wie die jeweils eigenen Fachinhalte - mal von einer anderen Seite aus - betrachtet werden können und so zu ertragreichen neuen Themen und Forschungsfeldern führen. Das vorliegende Buch untersucht diese Erweiterungsbewegungen und fragt nach dem »Bild« (im weitesten Sinne) als historische, für das gesamtkulturelle Gedächtnis aufschlussreiche »Quelle« und als »Zeugnis«. Das breitgefächerte Spektrum der versammelten Themen von Autoren und Autorinnen aus unterschiedlichen geisteswissenschaftlichen Disziplinen reicht hierbei von theoretisch-methodischen Fragestellungen, die für den Diskurs und die Kanonbildung relevant sind, bis hin zu Beiträgen, die das Thema der Publikation spezifisch im Kontext der Gattungen Malerei, Grafik oder Fotografie beleuchten. Doch auch audiovisuelle bewegte oder virtuelle, zum Jetzt-Zeitpunkt bereits verflüchtigte Bilder finden in Form von neuen Medien, Film und Kulturfernsehen Beachtung, da auch sie zum zentralen Bestandteil und Dokument einer kollektiven Erinnerung werden können. Mit Beiträgen von: Juerg Albrecht, Nadja Elia-Borer, Pietro Giovannoli, Daniel Hornuff, Kornelia Imesch, Philippe Kaenel, Fabian Probst, Caroline Recher, Severin Ruegg, Philipp Stoellger, Jakob Tanner, Mélanie Laurance Tanner, Carsten-Peter Warnke, Anja Zimmermann.

Pattern-based sensing of nucleotides in aqueous solution with a multicomponent indicator displacement assay

A multicomponent indicator displacement assay ( MIDA) based on an organometallic receptor and three dyes can be used for the identification and quantification of nucleotides in aqueous solution at neutral pH.

Points to consider for prioritizing clinical genetic testing services: a European consensus process oriented at accountability for reasonableness.

Given the cost constraints of the European health-care systems, criteria are needed to decide which genetic services to fund from the public budgets, if not all can be covered. To ensure that high-priority services are available equitably within and across the European countries, a shared set of prioritization criteria would be desirable. A decision process following the accountability for reasonableness framework was undertaken, including a multidisciplinary EuroGentest/PPPC-ESHG workshop to develop shared prioritization criteria. Resources are currently too limited to fund all the beneficial genetic testing services available in the next decade. Ethically and economically reflected prioritization criteria are needed. Prioritization should be based on considerations of medical benefit, health need and costs. Medical benefit includes evidence of benefit in terms of clinical benefit, benefit of information for important life decisions, benefit for other people apart from the person tested and the patient-specific likelihood of being affected by the condition tested for. It may be subject to a finite time window. Health need includes the severity of the condition tested for and its progression at the time of testing. Further discussion and better evidence is needed before clearly defined recommendations can be made or a prioritization algorithm proposed. To our knowledge, this is the first time a clinical society has initiated a decision process about health-care prioritization on a European level, following the principles of accountability for reasonableness. We provide points to consider to stimulate this debate across the EU and to serve as a reference for improving patient management.